Citrin Rebecca, Horowitz Joseph P, Reilly Anne F, Li Yimei, Huang Yuan-Shung, Getz Kelly D, Seif Alix E, Fisher Brian T, Aplenc Richard
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
PLoS One. 2017 Oct 23;12(10):e0186960. doi: 10.1371/journal.pone.0186960. eCollection 2017.
Mature B-cell non-Hodgkin lymphoma (B-NHL) constitutes a collection of relatively rare pediatric malignancies. In order to utilize administrative data to perform large-scale epidemiologic studies within this population, a two-step process was used to assemble a 12-year cohort of B-NHL patients treated between 2004 and 2015 within the Pediatric Health Information System database. Patients were identified by ICD-9 codes, and their chemotherapy data were then manually reviewed against standard B-NHL treatment regimens. A total of 1,409 patients were eligible for cohort inclusion. This process was validated at a single center, utilizing both an institutional tumor registry and medical record review as the gold standards. The validation demonstrated appropriate sensitivity (91.5%) and positive predictive value (95.1%) to allow for the future use of this cohort for epidemiologic and comparative effectiveness research.
成熟B细胞非霍奇金淋巴瘤（B-NHL）是一组相对罕见的儿童恶性肿瘤。为了利用行政数据在该人群中开展大规模流行病学研究，采用了两步法在儿科健康信息系统数据库中收集了2004年至2015年期间接受治疗的B-NHL患者的12年队列。通过ICD-9编码识别患者，然后根据标准B-NHL治疗方案对其化疗数据进行人工审核。共有1409名患者符合队列纳入标准。该过程在一个中心进行了验证，以机构肿瘤登记和病历审查作为金标准。验证显示出适当的敏感性（91.5%）和阳性预测值（95.1%），以便未来将该队列用于流行病学和比较效果研究。
